Key result
Inclisiran provides sustained LDL-C reduction, but real-world data after switching from evolocumab remain limited.
Why the study?
Real-world data on LDL-C control after switching from PCSK9 monoclonal antibodies to inclisiran remain limited.
Does transitioning from evolocumab to inclisiran maintain LDL-C control in patients with coronary artery disease?
Cohort (n=32)
Does transitioning from evolocumab to inclisiran maintain LDL-C control in patients with coronary artery disease?
Transitioning from evolocumab to inclisiran maintains stable LDL-C levels in most patients with coronary artery disease, though those with familial hypercholesterolemia may require closer monitoring.
Background: Inclisiran is a siRNA therapy that provides sustained reduction in low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing, but real-world data after switching from PCSK9 monoclonal antibodies remain limited. Methods and Results: We retrospectively analyzed 32 patients with coronary artery disease who transitioned from evolocumab to inclisiran. Median LDL-C was 27.0 mg/dL at baseline and remained stable at 3, 6, and 9 months (29.0, 30.5, and 29.5 mg/dL). Eight patients (25%) exceeded the LDL-C target (<70 mg/dL) at least once, more frequently among those with heterozygous familial hypercholesterolemia. Discontinuation occurred in 12.5%. Conclusions: Switching to inclisiran generally maintained LDL-C levels, although patients with familial hypercholesterolemia may require closer monitoring.
No takes yet. Share an insight, caveat, or question.
Tabata et al. (2026) conducted a cohort in Coronary artery disease (n=32). Inclisiran vs. Evolocumab (baseline) was evaluated on Median LDL-C at 9 months. Transitioning from evolocumab to inclisiran maintained stable median LDL-C levels (27.0 mg/dL at baseline vs 29.5 mg/dL at 9 months), though 25% exceeded the <70 mg/dL target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: